FLGR-242: What the Research Actually Shows (2026)

Search FLGR-242 and you will find catalog listings, forum speculation, and confident talk about muscle. What you will not find is a single peer-reviewed study that tested FLGR-242 under that name.

What is FLGR-242?

FLGR-242 is a supplier catalog designation for a compound marketed as a recombinant follistatin analog and myostatin inhibitor. No peer-reviewed human trial of FLGR-242 has been published. The science quoted around it belongs to follistatin and myostatin biology, which is related but not the same thing. Real Peptides does not carry FLGR-242 or follistatin.

The over-simplification worth correcting immediately is the idea that the name is a synonym for follistatin. Nobody outside the suppliers listing it has published a sequence, a molecular weight, a half-life, or a purity specification for this particular catalog item. Every mechanistic claim attached to FLGR-242 is borrowed from studies that used recombinant follistatin protein, follistatin gene constructs delivered by viral vector, or entirely different myostatin-pathway drugs. This page covers where the name comes from, what the follistatin literature genuinely reported, how the search variants relate to each other, and how researchers verify an unfamiliar vial before it enters an experiment.

What is FLGR-242?

FLGR-242 is a product designation used by research-chemical suppliers, not a molecule with an entry in the scientific literature. Run the term through PubMed and nothing comes back. Run it through a protein database and nothing comes back. That absence is the single most important fact about it, and it is the fact most pages discussing the compound quietly skip.

What suppliers say is that FLGR-242 is a recombinant follistatin analog intended for myostatin-pathway research. That is a marketing description. It is not a characterisation that has been independently confirmed, and the number in the name has no published meaning that we can trace. We are not going to guess at one. Inventing a molecular weight or a sequence for an uncharacterised catalog item is precisely the behaviour that makes this corner of the market difficult to navigate.

Our team has spent a long time reading certificates of analysis and supplier documentation across the follistatin category, and the pattern with names like FLGR-242 is consistent. The listing describes a function, not an identity. A functional description cannot be verified by mass spectrometry. An amino acid sequence can.

So treat the term as a label attached to material of unstated composition. If you want the underlying biology, follistatin is the subject with an actual literature behind it, and Follistatin-344 is the specific construct most of that work revolves around.

FLGR vs FLGR-242 vs 'FLGR 224' and 'FLGR 24'

These are all the same search. People type FLGR, FLGR peptide, 'FLGR 224 peptide', or 'FLGR 24 peptide' when they are looking for the same catalog item, and the variants are transcription errors rather than separate compounds. There is no published molecule called FLGR-224 and none called FLGR-24. If a listing uses one of those spellings, it is describing the same unverified material as FLGR-242.

Two disambiguations matter far more than the typos.

First, FLGR-242 is not FLRG. FLRG stands for follistatin-related gene product, also catalogued as FSTL3, and it is a real, well-described protein. Work published in the Journal of Biological Chemistry identified the myostatin propeptide and FLRG as myostatin-binding proteins circulating in serum (PMID 12194980). FLRG is an endogenous human protein studied in peer-reviewed research. FLGR-242 is a product name. The letter transposition between FLRG and FLGR is almost certainly where the catalog name came from, and conflating the two is the most common error we see in forum threads.

Second, FLGR is also a stock ticker symbol on public markets. It has nothing to do with peptides, follistatin, or myostatin. If search results jump between muscle biology and share prices, that is why.

FLGR-242 vs Follistatin-344 vs Follistatin-315

Follistatin-344 and Follistatin-315 are defined entities. FLGR-242 is not, and that asymmetry is the whole comparison.

Follistatin exists in several isoforms generated by alternative splicing and proteolytic processing. FS315 is the longer circulating form with an acidic C-terminal tail that reduces heparin binding. FS288 is the shorter, cell-surface-associated form with high heparin affinity. Work in the Journal of Biological Chemistry examined how these isoforms differ in heparin and activin binding (PMID 17409095). FS344 refers to the precursor transcript, the cDNA that encodes the 344-amino-acid preproprotein, and it is the construct used in human gene therapy work. The relationship between these names trips up almost everyone, which is why we wrote a separate explainer on whether follistatin and Follistatin-344 are the same thing.

The practical difference is traceability. A vial labelled Follistatin-344 can be checked against a known sequence by mass spectrometry. A vial labelled FLGR-242 cannot, because no reference sequence has been published for it. You can test what is in the vial. You cannot test whether it matches a specification that does not exist.

How is FLGR-242 described to work?

Suppliers describe FLGR-242 as working through myostatin inhibition, and that described mechanism is lifted directly from follistatin research rather than from any study of the compound itself.

Myostatin, also called GDF-8, is a transforming growth factor beta family ligand that restrains skeletal muscle growth. The foundational Nature paper by McPherron and colleagues showed that mice lacking the myostatin gene developed dramatically increased muscle mass (PMID 9139826). Follistatin entered the picture through work in PNAS demonstrating that follistatin binds myostatin and can regulate its activity (PMID 11459935).

The structural explanation came later. A Developmental Cell study resolved the follistatin:activin complex and showed that follistatin wraps the ligand in a way that blocks both type I and type II receptor binding surfaces (PMID 16198295). In plain terms, follistatin acts as a ligand trap rather than a receptor blocker. Myostatin and activin normally signal through the activin type II receptors ActRIIA and ActRIIB, which recruit type I receptors and drive SMAD2/3 phosphorylation. Sequester the ligand and the signal never reaches the receptor.

A PLoS One paper from Lee showed that follistatin overexpression in mice produced effects exceeding myostatin blockade alone, implying it engages multiple TGF-beta family ligands rather than myostatin in isolation (PMID 17726519). That breadth is a double edged feature, and we return to it under unknowns. The mechanism is covered in more depth in our guide to how Follistatin-344 works and our myostatin inhibition research guide.

None of those four studies used FLGR-242.

What research exists on FLGR-242?

None. There is no published preclinical study, no animal model, no phase 1 trial, and no case report that names FLGR-242. The honest answer to the research question is an empty set, and any page that implies otherwise is reselling follistatin citations under a different heading.

What does exist is a follistatin literature worth understanding on its own terms. A Muscle and Nerve review set out the rationale for follistatin as a therapeutic strategy in muscle disease (PMID 19208403). A Molecular Therapy paper reported a phase 1/2a trial delivering the FS344 cDNA by adeno-associated virus into the quadriceps of men with Becker muscular dystrophy (PMID 25322757). The same group later published results from follistatin gene therapy in sporadic inclusion body myositis (PMID 28279643), and a published critique in the same journal argued the functional-outcome claims in that work were unfounded (PMID 28927986). Read both. The dispute is as informative as the original report.

Here is the distinction that matters and that almost every FLGR-242 discussion collapses: those trials delivered a gene, packaged in a viral vector, injected into specific muscles under an investigational protocol. They did not administer a lyophilized recombinant protein. A gene therapy result cannot be transferred to a vial of powder. We unpack that gap in our write-up on follistatin gene therapy and muscle growth research, and we survey the broader evidence in our Follistatin-344 research review and our look at follistatin in sarcopenia research. A 2022 review in Advances in Clinical Chemistry traces myostatin from basic biology toward clinical application and is a reasonable orientation point (PMID 35152972).

What side effects and unknowns does the research report?

There is no safety data on FLGR-242, because there is no study of FLGR-242. Searches for FLGR-242 peptide side effects return speculation, not findings. What can be described honestly are the adverse signals reported in myostatin-pathway research generally, plus the unknowns specific to an uncharacterised vial.

The clearest cautionary result comes from ACE-031, a soluble ActRIIB decoy receptor. A randomized placebo-controlled trial in boys with Duchenne muscular dystrophy was stopped early after safety signals including nosebleeds and telangiectasias, small dilated surface blood vessels (PMID 27462804). That is a vascular effect, and it emerged because ActRIIB ligand blockade is not confined to skeletal muscle. The receptor family has roles across tissues.

A second signal comes from a PNAS study in which follistatin increased muscle mass in mice but weakened bone (PMID 32071240). Muscle and bone share regulatory inputs through the TGF-beta superfamily, so broad ligand trapping can push one tissue in a favourable direction while pushing another the wrong way.

Then there are the unknowns that attach specifically to FLGR-242: unverified identity, unverified purity, unknown endotoxin burden, unknown aggregation state, and unknown immunogenicity. Recombinant proteins of unstated expression system and unstated purification history carry residual host-cell protein risk that small synthetic peptides generally do not. Our page on long-term follistatin side effect research covers the published signals in more detail, and the same framing applies to growth-factor comparators in our review of IGF-1 LR3 side effects in the research.

How do researchers verify a vial of FLGR-242?

With an uncharacterised name, verification shifts from confirming a specification to establishing what is actually present. Three analytical methods carry the weight.

HPLC, high performance liquid chromatography, separates the sample by hydrophobicity and reports the relative area of the main peak against impurities. Research-grade documentation commonly reports main-peak purity at 98% or higher, though the figure is only meaningful alongside the chromatogram and the gradient conditions. A number on a PDF with no trace attached is a claim, not a result.

Mass spectrometry establishes identity by measuring molecular mass against the expected mass for a known sequence. This is exactly where FLGR-242 fails as a category. Without a published reference sequence, a mass spectrum confirms a mass, but it cannot confirm that the mass is correct, because there is no agreed target to compare against. Identity testing requires a known answer.

Third, batch traceability. A certificate of analysis should name the lot, the test date, the testing method, and ideally the independent laboratory that ran it. Our walkthrough on how to read a follistatin certificate of analysis applies line by line to any unfamiliar vial, and our published certificates of analysis show the format we hold our own catalog to. If the standard of documentation around a listing feels thinner than what you see on a high-purity research peptide page, that gap is the finding.

Reconstitution and storage, framed strictly as laboratory handling

Handling guidance for any recombinant protein of this class is generic cold-chain practice, and nothing here is administration guidance of any kind.

Lyophilized protein is typically stored frozen, commonly at minus 20 degrees Celsius or colder for long-term holding, protected from light and moisture. Once a sterile diluent is introduced, the material is held refrigerated at 2 to 8 degrees Celsius and treated as short-lived. Repeated freeze-thaw cycling is the most common cause of silent potency loss, because each cycle promotes aggregation and partial unfolding that no visual inspection can detect. Aliquoting into single-use volumes before freezing is standard practice for exactly that reason.

Reconstitution technique matters too. Directing diluent down the vial wall rather than onto the cake reduces shear and foaming, and foaming is a visible sign of protein denaturation at the air-liquid interface. Swirling beats shaking, every time.

For FLGR-242 specifically there is an additional problem: no supplier-independent stability study exists, so no evidence-based shelf life can be quoted. Our follistatin storage and stability guide, our reconstitution walkthrough, and our page on follistatin half-life and research dynamics cover handling for the characterised constructs where published data actually exists.

Legal and research-use-only status

FLGR-242 is not an approved drug in any jurisdiction we are aware of, and it has not been evaluated by any regulatory authority for safety or efficacy. It is sold, where it is sold, under research-use-only terms.

All compounds discussed on this page are sold for research use only and are not for human consumption.

That phrase is a legal and scientific boundary, not a formality. Research-use-only material is supplied without the manufacturing controls, batch release testing, and pharmacovigilance that accompany an approved medicine. Separately, agents acting on the myostatin pathway appear on the World Anti-Doping Agency Prohibited List, so the regulatory picture extends beyond medicines law into sport governance. Our overview of follistatin legal and regulatory status sets out the framework in more detail.

One practical note. If an animal-health question brought you to this page, that is a conversation for a licensed veterinarian, not a research-compound supplier. Research chemicals are not veterinary medicines.

What do researchers compare FLGR-242 with?

The three comparators that come up most often are Follistatin-344, ACE-031, and IGF-1 LR3, and they differ on the only axis that matters for research planning, which is how much verifiable evidence sits behind each. The table below sets out molecule type, target, evidence level, and availability side by side.

IGF-1 LR3 sits in a different pathway entirely, signalling through the IGF-1 receptor rather than trapping TGF-beta ligands, which is why it is a contrast rather than a substitute. We compare the two directly in our Follistatin-344 versus IGF-1 LR3 research comparison, and the receptor-level detail lives in our pages on IGF-1 LR3, its IGF-1 receptor mechanism, and the top IGF-1 LR3 studies. For researchers mapping the wider field, see our Follistatin-344 alternatives overview, the MK-677 comparison, the sermorelin comparison, and our combination research guide.

How we researched this page

Sources were PubMed-indexed literature on follistatin, myostatin, and ActRIIB signalling, read in full rather than by abstract. Where a dispute exists in the published record, such as the challenge to the inclusion body myositis functional outcomes, both the original paper and the critique are cited so the reader can judge.

Supplier product descriptions were treated as dated observations of how FLGR-242 is marketed, not as evidence of composition. No vendor is named. We performed no first-party testing of FLGR-242, we have never held the material, and we make no claim about what any given vial contains. Every specification we could not verify was omitted rather than estimated.

What If: FLGR-242 Sourcing Scenarios

What if a supplier sends a certificate of analysis with no sequence on it?

Treat the document as a purity estimate only, not an identity confirmation. Purity by HPLC tells you how much of a single species is present; it says nothing about which species. Without a stated amino acid sequence and a matching mass spectrometry result, the certificate cannot establish that the vial contains what the label claims.

What if two listings use different spellings, like FLGR-242 and FLGR 224?

Assume they refer to the same marketing category and verify each lot independently anyway. Spelling variation across suppliers indicates a name propagated through catalogs rather than through a reference standard. Where no reference standard exists, batch-to-batch consistency is unverifiable by definition, and two vials sharing a label are not evidence of sharing a composition.

What if the literature cited on a product page is all about follistatin?

Read it as evidence about follistatin, which it is, and not as evidence about the product. Citation borrowing is the dominant pattern in this niche. A study that used recombinant follistatin protein, an AAV-delivered FS344 construct, or a soluble ActRIIB decoy receptor tested those things. Extending those findings to an uncharacterised vial is an assumption, not an inference.

The uncomfortable truth about FLGR results

Let's be direct about this: there are no FLGR-242 results to report. Not weak results, not preliminary results, none. Searches for FLGR results surface anecdote and supplier copy, and anecdote about an uncharacterised compound is not data about anything, because nobody can confirm what was in the material being described.

The follistatin literature is genuinely interesting, genuinely contested, and genuinely incomplete, and it deserves to be read as itself rather than repackaged as a product claim. If outcomes are the question, our pages on follistatin and body composition research, what before-and-after claims actually rest on, and how long follistatin takes to work in the research deal with the published picture, limitations included.

The gap between a named molecule and a named product is the whole story here. FLGR-242 has a product name, a marketing description, and a search volume, which together create the impression of a known quantity. What it lacks is the one thing that would make any of the surrounding claims checkable: a published identity. Until that exists, the most scientifically defensible position is also the simplest one. The compound is unstudied, the citations around it belong to other molecules, and the honest answer to almost every question about it is that nobody knows yet.

Other names and spellings

Searches for this compound use several spellings that all refer to the same vendor-marketed product: FLGR 242, FLGR242, FLGR-242 peptide, FLGR 242 peptide, Follistatin FLGR242 and the shorthand FLGR peptide. "FLGR 224" and "FLGR 24" are common typos of the same name. None of these is FLRG (the follistatin-related gene product, FSTL3), and none is the FLGR stock ticker.